The estimated Net Worth of Theresa Wingrove is at least $4.81 millió dollars as of 2 February 2024. Dr Wingrove owns over 29,640 units of Immunogen stock worth over $1,032,982 and over the last 13 years he sold IMGN stock worth over $3,230,837. In addition, he makes $548,205 as Sr. VP of Regulatory Affairs & Quality at Immunogen.
Sign up
Dr Wingrove IMGN stock SEC Form 4 insiders trading
Dr has made over 12 trades of the Immunogen stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 29,640 units of IMGN stock worth $925,954 on 2 February 2024.
The largest trade he's ever made was selling 192,013 units of Immunogen stock on 15 September 2023 worth over $2,964,681. On average, Dr trades about 31,140 units every 102 days since 2011. As of 2 February 2024 he still owns at least 33,066 units of Immunogen stock.
You can see the complete history of Dr Wingrove stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Theresa G. Wingrove biography
Dr. Theresa G. Wingrove is the Sr. VP of Regulatory Affairs & Quality at Immunogen.
What is the salary of Dr Wingrove?
As the Sr. VP of Regulatory Affairs & Quality of Immunogen, the total compensation of Dr Wingrove at Immunogen is $548,205. There are 5 executives at Immunogen getting paid more, with Mark Enyedy having the highest compensation of $3,917,560.
How old is Dr Wingrove?
Dr Wingrove is 63, he's been the Sr. VP of Regulatory Affairs & Quality of Immunogen since . There are 4 older and 12 younger executives at Immunogen. The oldest executive at Immunogen, Inc. is Richard Wallace, 68, who is the Independent Director.
What's Dr Wingrove's mailing address?
Theresa's mailing address filed with the SEC is C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM, MA, 02451.
Insiders trading at Immunogen
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding... és Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
What does Immunogen do?
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
What does Immunogen's logo look like?
Complete history of Dr Wingrove stock trades at Immunogen
Immunogen executives and stock owners
Immunogen executives and other stock owners filed with the SEC include:
-
Mark Enyedy,
President, Chief Executive Officer, Director -
Anna Berkenblit,
Senior Vice President and Chief Medical Officer -
Thomas Ryll,
Vice President, Technical Operations -
Mark Joseph Enyedy,
Pres, CEO & Director -
Dr. Anna Berkenblit,
Sr. VP & Chief Medical Officer -
Dr. Theresa G. Wingrove,
Sr. VP of Regulatory Affairs & Quality -
Stacy A. Coen,
Sr. VP & Chief Bus. Officer -
Stephen McCluski,
Independent Chairman of the Board -
Kristine Peterson,
Independent Director -
Richard Wallace,
Independent Director -
Dean Mitchell,
Independent Director -
Mark Goldberg,
Independent Director -
Stuart Arbuckle,
Independent Director -
Theresa Wingrove,
Senior Vice President - Regulatory Affairs and Quality -
Stacy Coen,
Senior Vice President and Chief Business Officer -
Susan Altschuller,
Chief Financial Officer, Senior Vice President -
Kristen Harrington-Smith,
Sr. VP & Chief Commercial Officer -
Audrey Bergan,
VP & Chief HR Officer -
Courtney O'Konek,
Sr. Director of Corp. Communications & Investor Relations -
Dr. Thomas Ryll,
Sr. VP of Technical Operations -
Renee Lentini,
VP of Fin., Principal Accounting Officer & Corp. Controller -
Peter J. Williams,
VP, Business Development -
John Lambert,
Senior Vice President -
Joseph J Villafranca,
Director -
Richard J. Gregory,
Executive VP & CSO -
Charles Q Morris,
Executive VP & CDO -
Daniel M Junius,
Chief Financial Officer -
David Brannon Johnston,
Chief Financial Officer -
Ellie Harrison,
VP & Chief HR Officer -
Howard H Pien,
Director -
Lauren White,
SVP, CFO AND PFO -
David G Foster,
V.P.-Fin., Prin. Acctg. Off. -
Blaine H. Mc Kee,
EVP & Chief Business Officer -
Nicole Onetto,
Director -
Craig Barrows,
Executive VP, General Counsel -
Sandra Poole,
Senior VP, Tech Operations -
Mark B Skaletsky,
Director -
Gregory D Perry,
Chief Financial Officer -
James J O'leary,
Vice President -
Biochem Incshire Pharmaceut...,
-
Karleen Marie Oberton,
Senior Corporate Controller -
Virginia Lavery,
VP and Senior Controller -
Gregg Beloff,
Vice President and CFO -
Christopher U Missling,
Chief Financial Officer -
Capital, L.P.Morton Holding...,
-
David Warren Carter,
Director -
Mitchel Sayare,
Chief Executive Officer -
John Tagliamonte,
VP, Business Development -
Stuart Feiner,
Director -
Pauline Jen Ryan,
VP Business Development -
Walter Blattler,
Executive Vice President -
Isabel Kalofonos,
SVP & CHIEF COMMERCIAL OFFICER -
Tracey L Mc Cain,
Director -
Michael Vasconcelles,
EVP R&D & MEDICAL AFFAIRS -
Daniel Char,
SVP & CHIEF LEGAL OFFICER -
Helen M. Thackray,
Director -
Kristen Harrington Smith,
SVP & CHIEF COMMERCIAL OFFICER -
Renee Lentini,
VP & PRIN ACCTG OFFICER